文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

慢性肾脏病患者的心血管疾病流行病学和风险。

Epidemiology and risk of cardiovascular disease in populations with chronic kidney disease.

机构信息

Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.

Welch Center for Prevention, Epidemiology, and Clinical Research, Baltimore, MD, USA.

出版信息

Nat Rev Nephrol. 2022 Nov;18(11):696-707. doi: 10.1038/s41581-022-00616-6. Epub 2022 Sep 14.


DOI:10.1038/s41581-022-00616-6
PMID:36104509
Abstract

Chronic kidney disease (CKD) is defined by a low glomerular filtration rate or high albuminuria, and affects 15-20% of adults globally. CKD increases the risk of various adverse outcomes, but cardiovascular disease (CVD) is of particular relevance because it is the leading cause of death in this clinical population. CKD is associated with several CVD outcomes, including coronary heart disease, stroke, peripheral artery disease, arrhythmias, heart failure and venous thrombosis. Notably, CKD is particularly strongly associated with severe CVD outcomes such as CVD mortality, heart failure and lower extremity amputations. This broad impact of CKD on the cardiovascular system probably reflects the involvement of several pathophysiological mechanisms that link CKD to CVD development - shared risk factors (for example, diabetes and hypertension), changes in bone mineral metabolism, anaemia, volume overload, inflammation and the presence of uraemic toxins. Understanding the status of CKD is crucial for appropriate CVD risk prediction in CKD populations. However, major clinical guidelines are not consistent in their incorporation of CKD measures for CVD risk prediction. Mitigating CVD risk in patients with CKD effectively requires multidisciplinary care that involves nephrologists, cardiologists and other health professionals, as well as further work to address current research and implementation gaps.

摘要

慢性肾脏病(CKD)的定义为肾小球滤过率低或白蛋白尿高,影响全球 15-20%的成年人。CKD 增加了各种不良结局的风险,但心血管疾病(CVD)尤其相关,因为它是该临床人群的主要死亡原因。CKD 与多种 CVD 结局相关,包括冠心病、中风、外周动脉疾病、心律失常、心力衰竭和静脉血栓形成。值得注意的是,CKD 与严重 CVD 结局(如 CVD 死亡率、心力衰竭和下肢截肢)的相关性特别强。CKD 对心血管系统的广泛影响可能反映了几个将 CKD 与 CVD 发展联系起来的病理生理机制,这些机制包括共同的危险因素(如糖尿病和高血压)、骨矿物质代谢变化、贫血、容量超负荷、炎症和尿毒症毒素的存在。了解 CKD 的状况对于 CKD 人群中适当的 CVD 风险预测至关重要。然而,主要的临床指南在纳入 CKD 措施进行 CVD 风险预测方面并不一致。有效降低 CKD 患者的 CVD 风险需要多学科护理,涉及肾病学家、心脏病专家和其他卫生专业人员,以及进一步努力解决当前的研究和实施差距。

相似文献

[1]
Epidemiology and risk of cardiovascular disease in populations with chronic kidney disease.

Nat Rev Nephrol. 2022-11

[2]
Chronic kidney disease measures for cardiovascular risk prediction.

Atherosclerosis. 2021-10

[3]
Cardiovascular risk prediction in people with chronic kidney disease.

Curr Opin Nephrol Hypertens. 2016-11

[4]
Kidney Disease in Diabetes

2018-8

[5]
Clinical epidemiology of cardiovascular disease in chronic kidney disease prior to dialysis.

Semin Dial. 2003

[6]
Chronic kidney disease as cardiovascular risk factor in routine clinical practice: a position statement by the Council of the European Renal Association.

Eur J Prev Cardiol. 2022-12-7

[7]
Risks of Adverse Events in Advanced CKD: The Chronic Renal Insufficiency Cohort (CRIC) Study.

Am J Kidney Dis. 2017-9

[8]
Machine learning model for cardiovascular disease prediction in patients with chronic kidney disease.

Front Endocrinol (Lausanne). 2024

[9]
Prevalence of atheromatous and non-atheromatous cardiovascular disease by age in chronic kidney disease.

Nephrol Dial Transplant. 2020-5-1

[10]
Cardiovascular disease and its relationship with chronic kidney disease.

Eur Rev Med Pharmacol Sci. 2014-10

引用本文的文献

[1]
Combined effects of visual impairment and chronic kidney disease on all-cause mortality among middle-aged and older adults: a longitudinal, population-based cohort study in China.

BMJ Open. 2025-9-3

[2]
The Non-Traditional Cardiovascular Culprits in Chronic Kidney Disease: Mineral Imbalance and Uremic Toxin Accumulation.

Int J Mol Sci. 2025-8-17

[3]
Disparities in chronic kidney disease burden estimates: From different sources, definitions, and equations.

PLoS One. 2025-8-25

[4]
Global burden of chronic kidney disease and risk factors, 1990-2021: an update from the global burden of disease study 2021.

Front Public Health. 2025-7-24

[5]
Predicting Chronic Kidney Disease After Cisplatin Treatment Using Population-Level Data.

JAMA Oncol. 2025-8-21

[6]
Renal drug dosing practices and clinical outcomes in patients with kidney disease admitted at two referral hospitals in Northwest Ethiopia.

BMC Nephrol. 2025-8-20

[7]
Efficacy and safety of PCSK9 inhibitors in patients with chronic kidney disease.

BMC Nephrol. 2025-8-19

[8]
Defective autophagy in vascular smooth muscle cells promote uremic accelerated atherosclerosis.

Ren Fail. 2025-12

[9]
Association of Life's Essential 8 Score with All-Cause and Cardiovascular Mortality in Patients with Diabetic Nephropathy: A NHANES-Based Cohort Study.

J Multidiscip Healthc. 2025-8-6

[10]
Independent and joint impacts of high body mass index and aging on global burden of chronic kidney disease: insights from the Global Burden of Disease Study 2021.

Front Nutr. 2025-7-25

本文引用的文献

[1]
Efficacy and Safety of Belimumab in Patients With Lupus Nephritis: Subgroup Analyses of a Phase 3 Randomized Trial in the East Asian Population.

Am J Kidney Dis. 2023-3

[2]
Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis.

Eur Heart J. 2022-2-10

[3]
Indoxyl sulfate in uremia: an old idea with updated concepts.

J Clin Invest. 2022-1-4

[4]
ADAM17, A Key Player of Cardiac Inflammation and Fibrosis in Heart Failure Development During Chronic Catecholamine Stress.

Front Cell Dev Biol. 2021-12-13

[5]
Impact of Obesity in Kidney Diseases.

Nutrients. 2021-12-15

[6]
The interplay of fibroblasts, the extracellular matrix, and inflammation in scar formation.

J Biol Chem. 2022-2

[7]
New Insights to the Crosstalk between Vascular and Bone Tissue in Chronic Kidney Disease-Mineral and Bone Disorder.

Metabolites. 2021-12-7

[8]
Insights into Salt Handling and Blood Pressure.

N Engl J Med. 2021-11-18

[9]
Is the KDIGO Systolic Blood Pressure Target <120 mm Hg for Chronic Kidney Disease Appropriate in Routine Clinical Practice?

Hypertension. 2022-1

[10]
Chlorthalidone for Hypertension in Advanced Chronic Kidney Disease.

N Engl J Med. 2021-12-30

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索